Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2011-07-12
2011-07-12
O'Sullivan, Peter G (Department: 1621)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S234500, C544S116000, C544S119000, C544S231000, C544S235000, C544S236000, C544S237000
Reexamination Certificate
active
07977333
ABSTRACT:
Substituted and pyridines and pyridazines having angiogenesis inhibiting activity and the generalized structural formulawherein the ring containing A, B, D, E, and L is phenyl or a nitrogen-containing heterocycle; groups X and Y may be any of a variety of defined linking units; R1and R2may be defined independent substituents or together may be a ring-defining bridge; ring J may be an aryl, pyridyl, or cycloalkyl group; and G groups may be any of a variety of defined substituents. Pharmaceutical compositions containing these materials, and methods of treating a mammal having a condition characterized by abnormal angiogenesis or hyperpermiability processes using these materials are also disclosed.
REFERENCES:
patent: 3478028 (1969-11-01), Parsons et al.
patent: 3753988 (1973-08-01), Rodway et al.
patent: 3764598 (1973-10-01), Yurugi et al.
patent: 5089494 (1992-02-01), Iwase et al.
patent: 5324727 (1994-06-01), Iwase et al.
patent: 5849741 (1998-12-01), Watanabe et al.
patent: 6288064 (2001-09-01), Watanabe et al.
patent: 6689883 (2004-02-01), Dumas et al.
patent: 0534443 (1993-09-01), None
patent: 0722936 (1996-07-01), None
patent: 0920868 (1997-08-01), None
patent: 0682947 (1997-09-01), None
patent: 0534443 (1998-12-01), None
patent: 1453897 (1966-09-01), None
patent: 1516777 (1968-03-01), None
patent: 3106875 (1991-07-01), None
patent: WO 0009495 (1998-02-01), None
patent: WO 9835958 (1998-08-01), None
patent: WO 9852944 (1998-11-01), None
patent: WO 9858929 (1998-12-01), None
patent: WO 9911628 (1999-02-01), None
patent: WO 9962908 (1999-12-01), None
patent: WO 0059509 (2000-10-01), None
patent: WO 0110859 (2001-02-01), None
Biagi et al., Chemical Abstracts, vol. 126:89328, 1996.
Biagi et al., Chemical Abstracts, vol. 123:83329, 1995.
Biagli et al., Chemical Abstracts, vol. 123:111969, 1995.
Monge et al., Chemical Abstracts, vol. 120:95169, 1994.
Marchard et al., Chemical Abstracts, vol. 114:42612, 1991.
Andersen et al., Chemical Abstracts, vol. 112:55749, 1990.
Suzuki et al., Chemical Abstracts, vol. 90:152107, 1979.
Mitsuhashi et al., Chemical Abstracts, vol. 84:180170, 1976.
Sieja, Chemical Abstracts, vol. 78:137957, 1973.
Pons et al., Chemical Abstracts, vol. 71:81350, (1969).
Howe et al., Chemical Abstracts, vol. 71:21922, (1969).
Robba et al., Chemical Abstracts, vol. 69:10411, (1968).
Robba et al., Chemical Abstracts, vol. 66:95066, (1967).
Robba et al., Chemical Abstracts, vol. 66:94981, (1967).
Desimoni et al., Chemical Abstracts,vol. 66:55454, (1967).
Chemical Abstract: 15:256197; Uenishi, Keiji et al. “Preparations of 1(3-pyridylmethyl) phthalazines as blood platelet aggregation inhibitors”,Jpn.Kokai Tokkyo Koho, 6 pp 1992.
Ferrara, N. et al., “Molecular and Biological Properties of the Vascular Endothelial Growth Factor Family of Proteins”, Endocrine Reviews, 13, 18-32 (1992).
Neufeld, G. et al., “Vascular endothelial growth factor (VDGF) and its receptors”. FASEB J., 13, 9-22 (1999).
Shweiki, D. et al., “Vascular Endothelial growth factor induced by hypoxia may mediate hypoxia-initated angiogenesis”. Nature, 359, 843-848, (1992).
Mustonen, T. and Alitalo K., “Endothelial Receptor Tyrosine Kinases Involved in Angiogenesis”. Cell Biology, 129, 895-898 (1995).
Waltenberger, J. et al., “Different Signal Transduction Properties of KDR and Flt1, Two Receptors for Vascular Endothelial Growth Factor” J. Biol. Chem. 269, 26988-26995, 1994.
Seetharan, L. et al., “A unique signal transduction from FLT tyrosine kinase, a receptor for vascular endothelial growth factor VEGF”. Oncogene, 10, 135-147 (1995).
Shweiki, D. et al., “Induction of vascular endothelial growth factor expression by hypoxia and by glucose deficiency in multicell spheroids: Implications for tumor angiogenesis”. Proc. Nat'l. Acad. Sci. USA, 92, 768-772 (1995).
Grugel, S. et al., “Both v-Ha-Ras and v-Raf Stimulate Expression of the Vascular Endothelial Growth Factor in NIH 3T3 Cells,” J. Biol. Chem., 270, 25915-25919 (1995).
Rak, J. et al., “Mutant ras Oncogenes Upregulate VEGF/VPF Expression: Implications for Induction and Inhibition of Tumor Angiogenesis.” Cancer Research 55, 4575-4580 (1995).
Mattern, J., et al., “Association of vascular endothelial growth factor expression with intratumoral microvessel density and tumour cell proliferation in human epidermoid lung carcinoma.” Brit. J. Cancer, 73, 931-934 (1996).
Viglietto, G. et al., “Upregulation of vascular endothelial growth factor (VDGF) and downregulation of placenta growth factor (PIGF) associated with malignancy injuman thyroid tumors and cell lines”. Oncogene, 11, 1569-1579 (1995).
Brown, L. et al., “Expression of Vascular Permeability Factor (Vascular Endothelial Growth Factor) and its Receptors in Breast Cancer”. Human Pathology, 26, 86-91 (1995).
Brown, L. et al., “Expression of Vascular Permeability Factor (Vascular Endothethiel Growth Factor) and its Receptors in Adrenocarinomas of the Gastrointestinal Tract”. Cancer Research 53, 4727-4735 (1993).
Suzuki, K. et al., “Expression of Vascular Permeability Factor/Vascular Endothelial Growth Factor in Human Hepatocellular Carcinoma”, Cancer Research, 56, 3004-3009 (1996).
Brown, L, et al., “Increased Expression of Vascular Permeability Factor (Vascular Endothelial growth Factor) and its Receptors in Kidney and Bladder Carcinomas”, Am. J. Pathology, 143, 1255-1262 (1993).
Olson, T. et al., “Vascular Permeability Factor Gene Expression in Normal and Neoplastic Human Ovaries”, Cancer Research, 54, 276-280 (1994).
Guidi, A. J. et al., “Vascular Permeability Factor (Vascular Endothelial Growth Factor) Expression and Angiogenesis in Cervical Neoplasia”, J. Nat'l. Cancer Institute, 87; 1237-1245 (1995).
Hashimoto, M. et al., “Expression of Vascular Endothelial Growth Factor and its Receptor mRNA in Angiosarcoma”. Laboratory Investigation, 83, 859-863, (1995).
Plate, Karl H. et al., “Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo”. Nature, 359, 845-848 (1992).
Phillips, Heidi S. et al., “Intense focal expression of vascular endothelial growth factor mRNA in human intracranial neoplasms: association with regions of necrosis”. Int. J. Oncology, 2, 913-919 (1993).
Berkman, Richard A., et al., “Expression of the Vascular Permeability Factor/Vascular Endothethial Growth Factor Gene in Central Nervous System Neoplasms”, J. Clin. Invest. 91, 153-159 (1993).
Kim K. Jin, et al., “Inhibition of Vascular Endothelial Growth Factor-Induced Angiogenesis Suppresses Tumour Growth in vivo,” Nature, 362, 841-844 (1993).
Rockwell, P. and Goldstein, N. I., “Role of Protein Tyrosine Kinase Receptors in Cancer; Possibilities for Therapeutic Intervention”, Mol. And Cell. Differ., 3, 315-335 (1995).
Aiello, L. P., et al., “Vascular Endothelial Growth Factor in Ocular Fluid of Patients with Diabetic Retinopathy and other Retinal Disorders”. New England J. Med., 331, 1480-1487 (1994).
Pe'er, J., et al., “Hypoxia-Induced Expression of Vascular Endothelial Growth Factor by Retinal Cells is a Common Factor in Neovascularizing Ocular Diseases”, Lab. Invest., 72, 638-645 (1995).
Lopez, P. F. et al., “Transdifferentitated Retinal pigment Epithelial Cells are Immunoreactive for Vascular Endothelial Growth Factor in Surgically Excised Age-Related Macular Degeneration-Related Choroidal Neovascular Membranes”. Invest Opthamol. Vis. Sci., 37, 855-868 (1996).
Koch, A. E. et al., “Vascular Endothelial Growth Factor: A Cytokine Modulating Endothelial Function in Rheumatoid Arthritis,” J. Immunol., 152, 4149-4156 (1994).
Peacock, D. J., et al., “Angiogenesis Inhibition Suppresses Collagen Arthritis”, J. Exp. Med., 175, 1135-1138, (1992).
Brown, L., et al., “Increased Expression of Va
Boyer Stephen J.
Dixon Julie A.
Dumas Jacques P.
Joe Teddy K.
Kluender Harold C. E.
Bayer Healthcare LLC
DiCeglie, Jr. Nicholas J.
Edwards Angell Palmer & & Dodge LLP
Loren Ralph A.
O'Sullivan Peter G
LandOfFree
Substituted pyridines and pyridazines with angiogenesis... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Substituted pyridines and pyridazines with angiogenesis..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted pyridines and pyridazines with angiogenesis... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2649332